Clinical trials
Fibrosis clinical trials
Below are recruiting fibrosis clinical trials, each written for real people, not researchers. We’re tracking 440 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05200429Recruiting
Study of long-term effects of CFTR modulator medicines in CF
This observational study follows people with cystic fibrosis (CF) to understand the long-term impact of CFTR modulator medicines. It may help researchers see how these treatments work over time in real life.
Vancouver, British ColumbiaAges Any age - NCT05241418Recruiting
MRI study of heart scar using gadolinium in repaired heart defects
This trial looks at heart MRI images to see whether a contrast dye (gadolinium) can highlight scar-like areas after congenital heart problems have been repaired. It may help doctors better understand healing and plan care, especially for future heart procedures.
Boston, MassachusettsAges 13 years+ - NCT05248230RecruitingPhase 2
Study drug for adults with cystic fibrosis lung disease
This Phase 2 trial tests 4D-710 to improve lung health in adults with cystic fibrosis who either cannot take CFTR modulator medicines or are not doing well enough on them. You may be eligible if you have moderate lung function and stable oxygen levels, and you meet other safety and health requirements.
Birmingham, AlabamaAges 18 years+ - NCT05279040Recruiting
Trikafta plus exercise program for adults with cystic fibrosis
This study tests how starting Trikafta affects exercise ability and breathing in adults with cystic fibrosis. You may be asked to do supervised breathing and exercise tests to see if Trikafta helps your lung function and stamina.
Vancouver, British ColumbiaAges 19 years+ - NCT05310669Recruiting
Tests breathing effort using a nasal pressure sensor in IPF
This study measures how hard you breathe using a gentle nasal pressure device in people with idiopathic pulmonary fibrosis (IPF). It may help doctors better understand breathing mechanics in IPF and guide future care.
ModenaAges 18 years+ - NCT05365802RecruitingEarly Phase 1
PET scan to study lung scarring in people with ILD
This early-phase study uses a special PET scan to look at a substance linked to lung scarring (fibrosis) in people with ILD (interstitial lung disease). The goal is to see whether the scan can help measure lung disease activity and support future treatment decisions.
Los Angeles, CaliforniaAges 18 years+ - NCT05392881Recruiting
Lung disease biobank for adults followed at a university clinic
This study collects and stores samples and health information from adults being followed for interstitial lung disease or certain rare lung conditions. The goal is to help researchers study these diseases over time and improve future care.
Kansas City, KansasAges 18 years+ - NCT05504837RecruitingPhase 1
Test KB407 inhaled treatment for adults with cystic fibrosis
This Phase 1 study tests the safety of KB407 and how it works in adults with cystic fibrosis (CF). It may help researchers understand whether this inhaled treatment could become a future option for CF.
Gainesville, FloridaAges 18 years+ - NCT05571059RecruitingPhase 2
Ifetroban pills for idiopathic pulmonary fibrosis
This trial studies ifetroban, an oral medicine, in people with idiopathic pulmonary fibrosis (IPF) to see if it improves outcomes and is safe. It may be an option if your IPF is confirmed on lung scans and your lung function tests meet the trial thresholds.
La Mesa, CaliforniaAges 40 years+ - NCT05644717RecruitingPhase 4
Testing erugliflozin for fatty liver and diabetes control
This trial studies whether erugliflozin can reduce liver fat and liver scarring (fibrosis) while also improving blood sugar in people with type 2 diabetes and fatty liver disease (NASH/NAFLD). It’s designed for people who haven’t used certain diabetes medicines like SGLT2 inhibitors or insulin before.
Peshawar, KPKAges 18–65 - NCT05651724Recruiting
MASH screening study for people with diabetes or obesity
This study screens participants for MASH (a type of liver fat inflammation) using information about your health and risk factors. It may help you and your care team learn whether you could have MASH and need follow-up.
Brussels, Vlaams-brabantAges 18–75 - NCT05802264RecruitingPhase 1
Inhaled amphotericin B for healthy volunteers and cystic fibrosis
This early-phase study tests how different doses of an inhaled medicine (amphotericin B) work and are tolerated. It includes healthy adults and people with cystic fibrosis (CF) to see if the dose schedule is safe and potentially beneficial.
Canberra, Australian Capital TerritoryAges 16 years+ - NCT05818319Recruiting
Tracking kidney urine effects after a short pause in CF therapy
This study checks how a common cystic fibrosis (CF) medicine affects urine markers after briefly stopping it and then restarting. The goal is to better understand whether the treatment shift changes kidney-related signals in people with CF.
Aarhus C, Central JutlandAges 18 years+ - NCT05842681Recruiting
Azithromycin for early worsening of idiopathic pulmonary fibrosis
This trial studies whether adding azithromycin to standard care can help people whose idiopathic pulmonary fibrosis is starting to flare up (worsen) in the early stages. It’s mainly for adults who are not very sick and cannot require intensive breathing support.
AsyutAges 18–80 - NCT05874492Recruiting
Spa therapy for radiation-related skin fibrosis after cancer
This trial tests whether a spa therapy program can improve “fibrosis,” or stiffened/scarred tissue and related skin problems, after radiotherapy for breast cancer or upper head/neck cancers. It aims to see if treatment can improve quality of life for people who still have moderate-to-worse symptoms months after radiation.
BordeauxAges 18 years+ - NCT05905172RecruitingPhase 3
Hydronidone for long-term treatment of hepatitis B scarring
This Phase 3 study tests whether hydronidone capsules can help people with long-term hepatitis B–related liver scarring (fibrosis). It aims to track whether treatment reduces or delays serious liver complications over time.
Beijing, Beijing MunicipalityAges 18–65 - NCT05937815Recruiting
Study of Trikafta on Gut-Lung Connection in CF
This study is looking at how a new combination medicine (Trikafta) affects the lungs and gut in people with cystic fibrosis who carry the DeltaF508 mutation. It aims to understand how the medicine works in the body.
BordeauxAges 6–17 - NCT05974904Recruiting
Study links a liver-related cell marker to fatty liver damage
This study looks at existing health survey data to see whether a specific immune-cell marker (called HsCAR) is related to fatty liver disease and liver scarring. It may help researchers better understand which people are at higher risk for worsening liver damage.
Chongqing, Chongqing MunicipalityAges 18–90 - NCT05975983RecruitingPhase 2
Oral treatment test for idiopathic pulmonary fibrosis
This Phase 2 study tests whether an oral medication (INS018_055) can help people with idiopathic pulmonary fibrosis (IPF). You may be a fit if your lung function is in a certain range and your condition is stable.
Birmingham, AlabamaAges 40 years+ - NCT05982795Recruiting
How CF modulators affect lung bacteria
This study looks at how highly effective CF modulator therapies change the bacteria living in the lungs of people with cystic fibrosis. Understanding these changes may help improve future treatments.
Lebanon, New HampshireAges 18–99 - NCT05998629Recruiting
Sweat sensor test for cystic fibrosis
This trial tests a new skin sensor that measures sweat to help diagnose cystic fibrosis. It compares results from people with CF and healthy volunteers to see if the device works accurately.
Hershey, PennsylvaniaAges 18–80 - NCT06102980Recruiting
Liver stiffness test during endoscopy for fatty liver disease
This study uses an ultrasound probe during a routine endoscopy to measure liver stiffness, which can help detect liver scarring (fibrosis) in people with fatty liver disease (MASLD). If you are already scheduled for an endoscopy and have no signs of advanced liver scarring, you may be able to join.
Guayaquil, GuayasAges 18–79 - NCT06119997Recruiting
Liver fibrosis screening using simple blood tests in primary care
This trial uses a blood test (FIB-4) to find liver scarring (fibrosis) in people who haven't been tested before. It aims to catch advanced liver disease early, which can help you get treatment sooner.
GrenobleAges 18–70 - NCT06122233Recruiting
Digital self-management for fibrotic lung disease
This trial tests whether a digital self-management program (using a smartphone or tablet) helps people with fibrotic interstitial lung disease better manage their symptoms and quality of life. If you have this lung condition and can use a mobile device, this study could offer you extra support at home.
Sydney, New South WalesAges 18 years+
Hear when a new Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for fibrosis?
- Yes. Clin2 currently lists 440 recruiting fibrosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a fibrosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a fibrosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.